Seattle Genetics Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Seattle Genetics (SGEN) PT Lowered to $92 at RBC Capital
October 26, 2018 7:35 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Seattle Genetics (NASDAQ: SGEN) to $92.00 (from $98.00) while maintaining a Outperform rating.
The analyst notes the surprise Adcetris miss brings questions to 1L HL aspect of bull thesis.
... MoreSeattle Genetics (SGEN) Sinks Following Q3 Results, Q4 Outlook
October 25, 2018 5:40 PM EDTSeattle Genetics (NASDAQ: SGEN) is down 16% after-hours after the company reported Q3 EPS of ($0.34), $0.07 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $169.4 million versus the consensus estimate of $166.92 million.
The company sees Q4 ADCETRIS net product sales of $128-$133 million and FY 2018 ADCETRIS net product sales of $473-$478 million.
ADCETRIS... More
